Brief: Targovax Announces Encouraging Results From Part 1 Of The Oncos-102 And Keytruda Combination Trial In Anti-Pd1 Refractory Melanoma

Circio Holding ASA

08/07/2019 17:32

July 8 (Reuters) - Targovax ASA  TRVX.OL :
    * TARGOVAX ANNOUNCES ENCOURAGING RESULTS FROM PART 1 OF THE
ONCOS-102 AND KEYTRUDA COMBINATION TRIAL IN ANTI-PD1 REFRACTORY
MELANOMA
    * PART 1 SAFETY DATA SHOWS THAT SEQUENTIAL ONCOS-102 AND
KEYTRUDA
TREATMENT REGIMEN IS WELL TOLERATED
    * INNATE AND ADAPTIVE IMMUNE ACTIVATION OBSERVED IN NINE OUT
OF
NINE PATIENTS
    * TARGOVAX - PART 2 TRIAL ENROLLING PATIENTS WHERE SAFETY,
EFFICACY OF MORE INTENSIVE TREATMENT REGIMEN OF 12 ONCOS-102
INJECTIONS WILL BE EVALUATED

Source text for Eikon:  ID:nWkr84rDdg 
Further company coverage:  TRVX.OL 

 ((Reuters.Briefs@thomsonreuters.com;))